{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:58:38Z","timestamp":1793120318147,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Without available curative therapies for delta hepatitis (hepatitis delta virus [HDV]), hepatic decompensation and hepatocellular carcinoma (HCC) among HDV patients often necessitates liver transplantation (LT). The objective of this study was to evaluate outcomes of LT among hepatitis B virus (HBV)\/HDV patients in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We performed the first US-based retrospective study of patients who underwent LT for HDV compared with HBV (monoinfection) in the years 2002\u20132019. We evaluated posttransplant survival and predictors of survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>We identified a total of 152 HBV\/HDV and 5435 HBV patients who underwent LT. HDV patients were younger at transplant (52 versus 55, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), less commonly Asian (16% versus 36%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), more likely to be HCV Ab positive (42% versus 28%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and less likely to be listed for LT with HCC (38% versus 51%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001), more likely to have ascites (73% versus 64%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.019), had worse coagulopathy (mean INR 2.0 versus 1.82, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04), and were more likely to receive a HCV-positive donor organ (7% versus 3%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001). Post-LT overall survival and graft survival were similar between HDV and HBV patients, including among patients with HCC. Older age, HCV coinfection, HCC, and higher model for end-stage liver disease at transplant were associated with higher posttransplant mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>HDV patients were sicker and more likely to be listed for LT for decompensated disease compared with HBV patients. Post-LT survival was similar between HDV and HBV patients, in contrast to prior international studies that suggested worse post-LT survival in HBV patients due to higher rates of HBV reactivation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001253","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T22:10:04Z","timestamp":1640038204000},"page":"e1253","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era"],"prefix":"10.1097","volume":"8","author":[{"given":"Tatyana","family":"Kushner","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben L.","family":"Da","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hepatology, Sandra Atlas Bass Center for Liver Diseases and Transplantation, Barbara and Zucker School of Medicine for Hofstra\/Northwell Health, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryana","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Dieterich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Sigel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Saberi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY."},{"name":"Division of Gastroenterology\/Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jgh.12217","article-title":"Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California.","volume":"28","author":"Gish","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients.","volume":"66","author":"B\u00e9guelin","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2018.07.005","article-title":"Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia.","volume":"74","author":"Coghill","year":"2018","journal-title":"Int J Infect Dis"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.31055","article-title":"Economic and health care burdens of hepatitis delta: a study of commercially insured adults in the United States.","volume":"72","author":"Elsaid","year":"2020","journal-title":"Hepatology"},{"key":"R6-20240805","first-page":"523","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.","volume":"73","author":"Chen","year":"2020","journal-title":"Gut"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes.","volume":"63","author":"Kushner","year":"2015","journal-title":"J Hepatol"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1086\/655808","article-title":"Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users.","volume":"202","author":"Kucirka","year":"2010","journal-title":"J Infect Dis"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cld.2013.05.007","article-title":"Hepatitis delta: the rediscovery.","volume":"17","author":"Rizzetto","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"461.e1","DOI":"10.1053\/j.gastro.2018.09.058","article-title":"Pathogenesis of and new therapies for hepatitis D.","volume":"156","author":"Koh","year":"2019","journal-title":"Gastroenterology"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen.","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0168-8278(99)80203-7","article-title":"Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis.","volume":"30","author":"Lerut","year":"1999","journal-title":"J Hepatol"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2012.10.016","article-title":"Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes.","volume":"58","author":"Burra","year":"2013","journal-title":"J Hepatol"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/jvi.65.3.1099-1104.1991","article-title":"Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line.","volume":"65","author":"Wu","year":"1991","journal-title":"J Virol"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/jhep.2000.19288","article-title":"Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.","volume":"32","author":"Sagnelli","year":"2000","journal-title":"Hepatology"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"54","DOI":"10.14218\/JCTH.2015.00041","article-title":"Prevention and treatment of recurrent hepatitis b after liver transplantation.","volume":"4","author":"Maiwall","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.transproceed.2016.08.044","article-title":"Liver transplantation for hepatitis B in early adulthood: analysis of the United Network for Organ Sharing database.","volume":"48","author":"Rifai","year":"2016","journal-title":"Transplant Proc"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/TP.0b013e31822d4dc3","article-title":"Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data.","volume":"92","author":"Waki","year":"2011","journal-title":"Transplantation"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1600-6143.2006.01242.x","article-title":"Characteristics associated with liver graft failure: the concept of a donor risk index.","volume":"6","author":"Feng","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14309\/ajg.0000000000000954","article-title":"Risk factors for delta hepatitis in a North American cohort: who should be screened?","volume":"116","author":"Da","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R25-20240805","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval.","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"R26-20240805","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D.","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J Hepatol"},{"key":"R27-20240805","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.15619","article-title":"Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting.","volume":"51","author":"Ferrarese","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.15188","article-title":"Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.","volume":"49","author":"Brancaccio","year":"2019","journal-title":"Aliment Pharmacol Therap"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.transproceed.2019.01.163","article-title":"Recurrence of hepatitis D virus in liver transplant recipients with hepatitis B and D virus-related chronic liver disease.","volume":"51","author":"Serin","year":"2019","journal-title":"Transplant Proc"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s0004-2803.201800000-06","article-title":"Liver transplantation in hepatitis delta: south america experience.","volume":"55","author":"Lima","year":"2018","journal-title":"Arq Gastroenterol"},{"key":"R31-20240805","doi-asserted-by":"crossref","first-page":"789","DOI":"10.12659\/AOT.910176","article-title":"Transplant patients receiving long-term hepatitis B immunoglobulin prophylaxis.","volume":"23","author":"Beckebaum","year":"2018","journal-title":"Ann Transplant"},{"key":"R32-20240805","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.transproceed.2016.02.076","article-title":"Hepatiti B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus.","volume":"48","author":"Adil","year":"2016","journal-title":"Transplant Proc"},{"key":"R33-20240805","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.1840210211","article-title":"Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.","volume":"21","author":"Samuel","year":"1995","journal-title":"Hepatology"},{"key":"R34-20240805","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis.","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"R35-20240805","first-page":"496A","article-title":"A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated intereron lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV study.","volume":"66","author":"Hamid","year":"2017","journal-title":"Hepatology"},{"key":"R36-20240805","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study.","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"R37-20240805","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection.","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J Hepatol"},{"key":"R38-20240805","first-page":"912A","article-title":"Initial follow-up results from the REP 301 trial: safety and efficacy of REP2139-Ca and pegylated interferon alpha-2a in caucasian patients with chronic HBV\/HDV co-infection.","volume":"64","author":"Bazinet","year":"2016","journal-title":"Hepatology"},{"key":"R39-20240805","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:06:39Z","timestamp":1722834399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001253","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}